Moderna, Inc. (SWX:MRNA)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 72.65B +762.8% |
| Revenue (ttm) | 1.80B -27.6% |
| Net Income | -2.55B |
| EPS | -6.58 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25 |
| Open | 203.00 |
| Previous Close | 192.56 |
| Day's Range | 203.00 - 203.00 |
| 52-Week Range | 19.65 - 203.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna’s Cancer Vaccine Earns Praise from Doctors amid Stock Selloff
Biotech company Moderna ($MRNA) saw its shares fall by as much as 25% on Thursday, October 22, despite positive results from a late-stage trial of its personalized cancer vaccine. The…
The real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Moderna leaked data was positive, what's hurting MRNA stock then?
Moderna's (MRNA) leaked cancer-vaccine trial results looked “promising” on the surface, yet the biotech stock came under intense pressure late on Thursday and was weak on Friday morning too, although ...
MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results
Moderna (MRNA) shares plunged after a partial leak showed results for the company's cancer vaccine trial. As Alison Kosik points out, the results were positive but weren't enough for investors.
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thurs...
Friday's First Moves: MRNA Cancer Vaccine Trial Leaks, DECK Earnings, NCLH Downgrade
Moderna (MRNA) lost $24 billion in market cap Thursday after data for its cancer vaccine trial leaked. Diane King Hall says investor expectations were above what leaked results showed.
Moderna's Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
Moderna and Merck's cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.
Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today repo...
Why Is Moderna Stock (MRNA) Still Falling After Thursday’s 18% Plunge?
Shares of U.S. vaccine maker Moderna ($MRNA) fell another 6% to about $191 during Friday’s pre-market session, extending Thursday’s 17.57% plunge. The earlier decline came after the full results of…
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...
Moderna melanoma data fall short of highest expectations, says Citi
Citi analyst Geoff Meacham says Moderna (MRNA) shares dropped yesterday after leaked, then later confirmed, Phase 3 INTerpath-001 data demonstrated intismeran plus pembrolizumab reduced the risk of re...
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Moderna ($MRNA) and BioNTech ($BNTX) are biotech stocks focused on cancer vaccines as they enter their next growth phase. According to TipRanks Comparison Stock tool, one stock offers upside potential...
Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk the drop in Moderna's stock following new cancer vaccine data.
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Moderna shares are taking a hit after the leak of highly anticipated details about the company's vaccine for the skin cancer melanoma.
Why Moderna stock plunged despite positive cancer vaccine trail results?
Moderna shares MRNA plunged on Thursday after partial data from its closely watched cancer vaccine trial leaked ahead of a scheduled presentation at the European Society for Medical Oncology conferenc...
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Moderna shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck triggered what analysts called a "sell-the-news" reaction after a months-...
Moderna selloff after data leak ‘a sell the news event,’ says Bernstein
Bernstein notes that leaked INTerpath-001 Phase 3 data posted by Oncology Central appeared to show “a strong result” for intismeran autogene plus Keytruda in the Phase 3 adjuvant high-risk melanoma…
Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Moderna, Inc. ("Moderna" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is invest...
Merck intismeran data concerns look ‘overdone,’ says Wells Fargo
After detailed data for the Phase 3 INTerpath-001 trial evaluating intismeran autogene in adjuvant melanoma was leaked, and then released by Merck (MRK) and Moderna (MRNA), Wells Fargo said the…
Merck, Moderna say INTerpath-001 trial data demonstrates favorable OS trend
Merck (MRK) and Moderna (MRNA) announced detailed positive recurrence-free survival and distant metastasis-free survival results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene, a ...
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence...
Moderna Stock Crashes 25% After Cancer-Vaccine Data Leak
Moderna shares tumbled as reported results for its cancer vaccine with Merck circulated ahead of a planned conference presentation.
TD comments on ‘unsubstantiated’ melanoma data from Moderna
TD Cowen analyst Tyler Van Buren says the “unsubstantiated” individualized neoantigen therapy data leaked today suggest a “compelling” Phase III result, within the “exceptional range” of key opinion l...
Moderna shares plunge after leak of partial cancer vaccine data
Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck. In this article MRNA